Psoriasis Treatment Options: Topicals, Biologics, and the IL-17/IL-23 Revolution

The Immune Skin Disease Affecting 125 Million People Worldwide

Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting approximately 3% of the global adult population — roughly 125 million people, including 7.5 million Americans. It is characterized by the accelerated turnover of keratinocytes (skin cells completing their lifecycle in 3–5 days rather than the normal 28–30 days), driven by dysregulated T-cell activity and inflammatory cytokines, producing the hallmark thick, scaly, erythematous plaques. While most cases are plaque psoriasis (psoriasis vulgaris), the disease manifests in several forms including guttate, inverse, pustular, and erythrodermic psoriasis. Up to 30% of psoriasis patients develop psoriatic arthritis, an inflammatory joint disease that can cause irreversible joint damage if untreated.

Modern biologics have transformed the treatment landscape so dramatically that "clear or almost clear skin" — unthinkable for most patients a generation ago — is now a realistic treatment goal for the majority.

Understanding the Immunological Mechanism

The pathogenic cascade in plaque psoriasis begins with dendritic cell activation — triggered by environmental factors (infections, trauma, stress, medications) in genetically predisposed individuals — leading to the production of IL-12 and IL-23. IL-23 drives differentiation and expansion of Th17 cells, which produce IL-17A and IL-17F, cytokines that directly stimulate keratinocyte proliferation and recruit neutrophils. This IL-23/Th17/IL-17 axis is the central therapeutic target of the most effective modern biologics. TNF-alpha, produced by Th1 cells and macrophages, amplifies inflammation and is targeted by the older generation of anti-TNF biologics that were repurposed from rheumatoid arthritis.

Topical Therapies: First-Line for Mild Disease

For mild psoriasis — defined as affecting less than 3–10% of body surface area without significantly impacting quality of life — topical therapies remain the foundation of treatment. Severity is often better assessed by location (palms, soles, nails, genital area, scalp, and face are disproportionately impairing) than by percentage of body surface area alone.

• Topical corticosteroids: Most commonly prescribed; available in classes I–VII by potency; reduce inflammation, proliferation, and vasodilation; highly effective for acute flares; side effects with prolonged use include skin atrophy, striae, telangiectasias, and systemic absorption (particularly in skin folds and on face); tachyphylaxis limits continuous use
• Vitamin D3 analogs (calcipotriol/calcipotriene, calcitriol): Normalize keratinocyte differentiation; similar efficacy to mid-potency corticosteroids; no skin atrophy risk; irritating on face and flexures; often combined with corticosteroids (Taclonex/Dovobet) for synergistic effect with reduced side effects
• Tapinarof (Vtama) and roflumilast foam (Zoryve): New non-steroidal topical agents FDA-approved 2022–2023; tapinarof is an aryl hydrocarbon receptor agonist; roflumilast is a PDE4 inhibitor; both safe for sensitive areas including face and skin folds; potential for continued use without atrophy
• Calcineurin inhibitors (tacrolimus, pimecrolimus): Off-label for face and intertriginous areas where steroids are inappropriate; moderate efficacy

Phototherapy: Underused and Highly Effective

Phototherapy — particularly narrowband UVB (NB-UVB, 311 nm) — is one of the most effective and safest treatments for moderate-to-severe psoriasis affecting large body surface areas. NB-UVB suppresses cutaneous T-cell activation and induces T-cell apoptosis in the skin. Treatment requires 3 sessions per week for 8–12 weeks; approximately 60–80% of patients achieve PASI-75 (75% reduction in Psoriasis Area and Severity Index score). Excimer laser (308 nm) delivers targeted UVB to individual plaques and is effective for limited, treatment-resistant areas. PUVA (psoralen + UVA) is more effective than NB-UVB for thick plaques but carries higher carcinogenicity risk with cumulative exposure and requires avoiding sun exposure after treatment.

Systemic Non-Biologic Treatments

The Biologic Revolution: IL-17 and IL-23 Inhibitors

The introduction of IL-17 and IL-23 inhibitors represents the most significant advance in psoriasis treatment in a generation. These biologics achieve PASI-90 (90% skin clearance) in 50–80% of patients and PASI-100 (complete clearance) in 30–50% — response rates that were considered impossible with older therapies.

• IL-17A inhibitors (secukinumab/Cosentyx, ixekizumab/Taltz): PASI-90 rates of 55–65% at 12 weeks; among the fastest-acting biologics; risk of Candida infections (5–7%); caution in inflammatory bowel disease (may worsen IBD)
• IL-17 receptor inhibitor (bimekizumab/Bimzelx, FDA 2023): Blocks both IL-17A and IL-17F; PASI-90 of 67–68%, PASI-100 of 43–46% at week 16; impressive complete clearance rates; higher Candida infection rates than IL-17A-only inhibitors
• IL-23 (p19) inhibitors (guselkumab/Tremfya, risankizumab/Skyrizi, tildrakizumab/Ilumya): PASI-90 rates of 70–75% at week 24; more durable responses than anti-TNF or IL-17 (responses maintained at lower frequencies with quarterly dosing); no IBD worsening signal; risankizumab PASI-100 at 56% at week 52
• IL-12/23 inhibitor (ustekinumab/Stelara): Earlier generation IL-23 blocker (p40 subunit); PASI-75 of 65–70%; less potent than p19-specific agents but well-tolerated long-term; convenient dosing (SC q12 weeks after loading)

Psoriatic arthritis accompanies skin disease in up to 30% of patients and often goes undiagnosed. IL-17 and IL-23 inhibitors, as well as anti-TNF agents, effectively treat both skin and joint manifestations.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.